EUVIMEDEUVIMED entdecken
Crossref

A Novel Mechanism of hPRL-G129R, a Prolactin Antagonist, Inhibits Human Breast Cancer Cell Proliferation and Migration

Ruonan Li iD, Yu Yang, Hainan Lan, Yuesi Wang, Zihan Ge, Xingjie Liu, Yixuan Zhou, Wei Zhang, Li Xian, Hongxuan Yuan

Endocrinology · 2023

DOI: 10.1210/endocr/bqad158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, 2023. Verfasst von Ruonan Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medicine and Pharmacy Research Center, Binzhou Medical University, Yantai 264003, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Prolactin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China-Young Scientists Fund, Scientific Research Launch Fund of Binzhou Medical College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prolactin (PRL) and its receptor, PRLR, are closely related to the occurrence and development of breast cancer. hPRL-G129R, an hPRLR antagonist, has been found to induce apoptosis in breast cancer cells via mechanisms currently unknown. Recent studies have indicated that PRLR exhibits dual functions based on its membrane/nucleus localization. In that context, we speculated whether hPRL-G129R is a dual-function antagonist. We studied the internalization of the hPRLR-G129R/PRLR complex using indirect immunofluorescence and Western blot assays. We found that hPRL-G129R not only inhibited PRLR-mediated intracellular signaling at the plasma membrane, but also blocked nuclear localization of the receptor in T-47D and MCF-7 cells in a time-dependent manner. Clone formation and transwell migration assays showed that hPRL-G129R inhibited PRL-driven proliferation and migration of tumor cells in vitro. Further, we found that increasing concentrations of hPRL-G129R inhibited the nuclear localization of PRLR and the levels of signal transducer and activator of transcription (STAT) 5 in tumor-bearing mice and hPRL-G129R also exerted an antiproliferative effect in vivo. These results indicate that hPRL-G129R is indeed a dual-function antagonist. This study lays a foundation for exploring and developing highly effective agents against the proliferation and progression of breast malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsProlactinAnimalsFemaleHumansMiceCell ProliferationReceptors, ProlactinTumor Cells, Cultured

Stichwörter der Autor:innen

PRLRbreast cancerdual functions antagonisthPRL-G129Rnuclear localization

Substanzen

Prolactinprolactin, Arg(129)-Receptors, Prolactin

Autor:innen und Institutionen

  • Medicine and Pharmacy Research Center, Binzhou Medical University, Yantai 264003, China.
  • State Key Laboratory of Animal Nutrition, Ministry of Agriculture Key Laboratory of Animal Genetics Breeding and Reproduction, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, China.
  • College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, China.
  • College of Medicine, Yanbian University, Yanji 133002, China.

ORCID-Profile: Ruonan Li

Förderung

  • National Natural Science Foundation of China-Young Scientists Fund
  • Scientific Research Launch Fund of Binzhou Medical College

Zitieren

APA

Li, R., Yang, Y., Lan, H., Wang, Y., Ge, Z., Liu, X., Zhou, Y., Zhang, W., Xian, L., & Yuan, H. (2023). A Novel Mechanism of hPRL-G129R, a Prolactin Antagonist, Inhibits Human Breast Cancer Cell Proliferation and Migration. Endocrinology. https://doi.org/10.1210/endocr/bqad158

Vancouver

Li R, Yang Y, Lan H, Wang Y, Ge Z, Liu X, et al. A Novel Mechanism of hPRL-G129R, a Prolactin Antagonist, Inhibits Human Breast Cancer Cell Proliferation and Migration. Endocrinology. 2023. doi:10.1210/endocr/bqad158

BibTeX
@article{Li2023,
  author = {Li, Ruonan and Yang, Yu and Lan, Hainan and Wang, Yuesi and Ge, Zihan and Liu, Xingjie and Zhou, Yixuan and Zhang, Wei and Xian, Li and Yuan, Hongxuan},
  title = {A Novel Mechanism of hPRL-G129R, a Prolactin Antagonist, Inhibits Human Breast Cancer Cell Proliferation and Migration},
  journal = {Endocrinology},
  year = {2023},
  doi = {10.1210/endocr/bqad158}
}
Kostenlos starten →